Mangoceuticals, Inc.
MGRX
$2.49
-$0.08-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -15.80% | 52.24% | 245.65% | 670.89% | 8,119.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.80% | 52.24% | 245.65% | 670.89% | 8,119.10% |
| Cost of Revenue | -21.37% | 54.52% | 256.44% | 578.99% | 7,217.07% |
| Gross Profit | -11.94% | 50.61% | 238.07% | 740.10% | 8,706.12% |
| SG&A Expenses | -15.27% | 12.13% | 26.49% | 84.67% | 304.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.86% | 25.26% | 43.94% | 115.10% | 304.21% |
| Operating Income | -2.40% | -23.20% | -35.39% | -100.03% | -271.56% |
| Income Before Tax | 5.48% | -27.45% | -40.12% | -97.83% | -356.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.48% | -27.45% | -40.12% | -97.83% | -356.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.49% | -27.43% | -40.11% | -97.83% | -356.58% |
| EBIT | -2.40% | -23.20% | -35.39% | -100.03% | -271.56% |
| EBITDA | 6.55% | -23.32% | -62.67% | -196.96% | -897.66% |
| EPS Basic | 45.88% | 26.79% | 15.84% | -19.09% | -227.32% |
| Normalized Basic EPS | 49.49% | 26.79% | 15.84% | -19.08% | -227.31% |
| EPS Diluted | 45.88% | 26.79% | 15.84% | -19.09% | -227.32% |
| Normalized Diluted EPS | 49.49% | 26.79% | 15.84% | -19.08% | -227.31% |
| Average Basic Shares Outstanding | 89.11% | 75.19% | 67.30% | 69.57% | 54.64% |
| Average Diluted Shares Outstanding | 89.11% | 75.19% | 67.30% | 69.57% | 54.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |